AI Health Technology Posts Steep Revenue Drop and Sustained Loss for 2025

Miji International Holdings Limited ( (HK:1715) ) just unveiled an update.

AI Health Technology Limited reported a sharp decline in revenue to RMB47.4 million for the year ended 31 December 2025, down from RMB91.9 million a year earlier, while gross profit fell to RMB4.3 million but the gross margin improved to 9.0% from 7.1%. The group remained loss-making, with net loss essentially unchanged at about RMB36.0 million and higher basic and diluted loss per share, reflecting ongoing cost pressures from selling, administrative and R&D expenses despite some reversal of impairment on financial assets.

Finance costs decreased year on year, but overall operating loss widened slightly as other income dropped and the company recorded losses from its joint venture and associate. The results underscore continued financial strain and execution challenges for the health-tech group, implying limited near‑term relief for shareholders as it works to stabilize revenue and move toward profitability in a competitive market environment.

The most recent analyst rating on (HK:1715) stock is a Hold with a HK$0.48 price target. To see the full list of analyst forecasts on Miji International Holdings Limited stock, see the HK:1715 Stock Forecast page.

More about Miji International Holdings Limited

AI Health Technology Limited is a Cayman Islands–incorporated company listed in Hong Kong that operates in the health technology sector. The group focuses on technology-driven healthcare solutions and related products and services, positioning itself within the broader medical and health-tech market in mainland China and possibly other regions through its foreign operations.

Average Trading Volume: 795,848

Technical Sentiment Signal: Buy

Current Market Cap: HK$205.6M

See more insights into 1715 stock on TipRanks’ Stock Analysis page.